hPD-L1

通过同源重组，将小鼠基因Cd274进行人源化修饰。与此相似的品系还有hPD-L1(2)(NM-HU-190039),详细信息请咨询技术顾问。

Fig1. Expression of PD-L1 in the spleen lymphocytes collected from homozygous humanized PD-L1 mice and wild-type mice is detected by FACS. The results showed that the expression of human PD-L1 can be detected in both T cells and B cells collected from the spleen of homozygous humanized PD-L1 mice. (Completed in collaboration with CrownBio)

Fig2. Immunotype in blood , spleen and bone marrow in hPD-L1 mice.  

Fig3. Immunotype in blood in hPD-L1 mice. 

Fig4. Immunotype in spleen in hPD-L1 mice. 

Fig5. Immunotype in bone marrow in hPD-L1 mice. 

Fig6. In vivo validation of anti-tumor efficacy in a MC38 tumor-bearing model of humanized PD-L1 mice. Homozygous humanized PD-L1 mice were inoculated with MC38 colon cancer cells (expressing human PDL1 rather than murine PD-L1). After the tumors grew to 100 mm3, the animals were randomly assigned into a control group and a treatment group (n=5). The results showed: The antibodies targeting human PD-L1 were associated with a very significant anti-tumor effect (TGI: tumor growth inhibition, p < 0.001), demonstrating that the humanized PD-L1 mice are a good in vivo model for validating the efficacy of antibodies targeting human PD-L1.